Can insulin resistance and hepatic metabolic stress alter androgen balance?

Metabolic dysfunction and liver health are relevant to androgen interpretation in a 52-year-old man, but they do not produce one uniform hormonal pattern. The overall claim is supported: insulin resistance and hepatic metabolic stress are associated with steroid-metabolic remodeling and can affect androgen balance through several interconnected pathways.

Clinical and metabolic evidence

• Insulin resistance is associated with urinary steroid-metabolite indices of altered 5α-reductase, 21-hydroxylase, and 11β-HSD activity. In overweight/obese adults followed for 5 years, higher baseline 5α-reductase activity predicted deterioration in fasting and glucose-challenge insulin measures and HOMA2-IR.
• Across MASLD, steroid handling changes with phenotype and fibrosis stage: simple steatosis has been associated with increased cortisol clearance and A-ring reduction, whereas steatohepatitis may show greater 11β-HSD1-mediated cortisol regeneration. Advanced fibrosis is linked to lower hepatic AKR1D1 expression and sex-specific changes in androgen sulfation/glucuronidation.
• Hepatic CYP3A4/AKR1D1 metabolism and UGT2B15/UGT2B17 glucuronidation are established determinants of testosterone and related-steroid clearance. Metabolic liver stress can therefore plausibly alter androgen concentrations, although direct human evidence for insulin resistance changing these specific enzyme activities remains limited.

SHBG and peripheral conversion mechanisms

• The strongest causal mechanistic pathway involves hepatic lipogenesis: glucose/fructose or palmitoyl-CoA reduces HNF-4α activity, allowing COUP-TF1 replacement at the SHBG promoter and suppressing SHBG transcription/secretion. Preventing lipogenesis prevented both HNF-4α loss and SHBG suppression.
• Lower SHBG commonly accompanies insulin resistance and steatosis. This can lower total testosterone and alter bound-versus-unbound hormone distribution; low total testosterone alone does not establish low biologically available androgen.
• Insulin resistance also correlates with metabolite patterns consistent with increased 5α-reductase activity independently of fat mass. Pharmacologic 5α-reductase inhibition lowers circulating DHT, confirming that peripheral conversion can materially alter androgen balance.

Bottom line

• Metabolic and hepatic dysfunction can affect androgen measures through SHBG, hepatic clearance/conjugation, and peripheral conversion. Effects are context-, tissue-, and disease-stage-dependent; interpretation should consider SHBG and validated free-testosterone assessment alongside metabolic and liver status.